Comparison Between Effect of Adrenaline and Without Adrenaline in Tumescent Solutions on Bleeding Control of Skin Graft Donor Site.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-17

Study Completion Date

2021-03-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to appraise if various concentration of adrenaline containing tumescent has any significant role in bleeding at skin graft donor site bleeding through photographic assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Lidocaine and Adrenaline Soaked Gauze Versus Normal Saline Soaked at Skin Graft Donor Site of Thigh

NCT04344483

Non-healing Wound

COMPLETED NA

A Single Center Trial of Donor Site Wound Dressings After Split Thickness Skin Grafting.

NCT06044519

Donor Site Complication Skin Graft Scar

COMPLETED PHASE4

Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting

NCT02012569

Burns Traumatic Lesions

COMPLETED PHASE2

Aloe Vera vs Paraffin Tulle Dressings for Pain Management in Split Thickness Skin Graft Donor Sites

NCT07057557

Skin Graft Wounds Donor Site Complication Pain, Postoperative +1 more

RECRUITING NA

Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting

NCT00371215

Surgical Hemostasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tumescent solutions will be prepared by adding 30cc of Ringer's lactate and 10cc of lignocaine 2%, with 1cc of adrenaline of 1:200,000 (which will be prepared by adding 1cc of adrenaline of 1:1000 conc. with 200ml of normal saline marked as solution "A" and without adrenaline marked as solution "B" to form the two different tumescent solutions. Both solutions with be topically applied in soaked gauzes for around 10 minutes. Solution A will be applied over the anterior side of thigh while solution B will be applied over lateral side of thigh.

Tumescent solutions will be prepared around 10 minutes before applying. After 10 min Split-thickness skin graft donor sites will be harvested with a Dermatome adjusted on with a randomized setting to harvest a fixed depth of wound depth. After harvesting skin graft the donor site wound will be photographed.

The apparent severity of bleeding will be scored on an ordinal scale from 0 to 5 (0=no bleeding/staining, 1=minimal bleeding/staining, 2=mild bleeding/staining, 3=moderate bleeding/staining, 4=moderately severe bleeding/staining, 5=severe bleeding/staining by two independent surgeons. At last photographs will be compared with pre-infiltration records in each side. Skin graft donor and recipient site will be inspected on the 5th post-operative day

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bleeding Time

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tumescent with adrenaline

skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution containing adrenaline.

Group Type ACTIVE_COMPARATOR

tumescent with adrenaline

Intervention Type OTHER

skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.

Tumescent without adrenaline

skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution not containing adrenaline.

Group Type ACTIVE_COMPARATOR

tumescent without adrenaline

Intervention Type OTHER

skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tumescent with adrenaline

skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.

Intervention Type OTHER

tumescent without adrenaline

skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age above 18 years

* both genders
* non hypertensive patients
* Hemoglobin levels more than 10 g/dl
* Platelet count above 150 x 10E9/L
* Wounds for more than 6 weeks